BUFFALO, N.Y., Sept. 10, 2012 /PRNewswire/ -- Kinex Pharmaceuticals, LLC announced the appointment of Mr. Patrick (Pat) Gallagher to the position of Vice President, Business Development and Investor Relations. Mr. Gallagher will report to Johnson Lau, MBBS, MD, FRCP, Kinex's Chief Executive Officer.
"Pat joins Kinex's management team at a time when his experience will be invaluable to the strategic growth of Kinex," said Dr. Johnson Lau. "Having known Pat for 12 years, I am delighted to welcome his deep insight and expertise in the biotechnology space, which will be instrumental in helping us to plan for our next phase of company growth. He was an early investor in Kinex and we have enjoyed his many years of invaluable advice to the company."
"Pat's vast network in both the biotechnology space and Wall Street will be extremely useful in assisting us to navigate through the next stage of company development," stated Mr. Chuck Lannon, Vice President of the Board and Chair of the Nomination and Corporate Governance Committee.
"This strong vote of confidence in Kinex and our pipeline from a Wall Street veteran such as Pat sends a powerful message about the strength of our team and the value of our products," said Dr. Jean-Pierre Sommadossi, Board member and Founder and former Chairman and CEO, Idenix.
Mr. Gallagher, CFA is an accomplished Capital Markets Executive, Advisor, and Investor with a distinguished record of success in both the public and private markets. He has nearly 20 years of experience on Wall Street and extensive expertise in alternative investments, capital markets, and marketing. He is a founding partner and was CEO of BDR Research Group, LLC; a healthcare focused institutional research boutique specialized in providing services for clients in the healthcare investing, financing, and operations areas. Mr. Gallagher is also a Managing Director of Potomac Management Group, a strategic consulting group. Prior, Mr. Gallagher worked for investment and research firms Kidder Peabody, PaineWebber and New Vernon Associates.
About Kinex Pharmaceuticals, LLC
Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica and Opal to discover and develop novel drugs for oncology and immune-modulatory diseases. More information of Kinex Pharmaceuticals can be found at www.kinexpharma.com
Kinex Pharmaceuticals, LLC Caution Regarding Forward-looking Information
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
SOURCE Kinex Pharmaceuticals, LLC